AstraZeneca Shares Advance Amid Policy Shifts and Valuation Scrutiny

AstraZeneca Shares Advance on Policy Shifts

AstraZeneca Plc (AZN) shares experienced a significant advance of 14.3% in the past week, pushing its year-to-date gains to 20.2%. This upward movement is primarily attributed to a recalibration of investment strategies by the British-Swedish pharmaceutical giant, particularly in response to shifting governmental policies in both the United Kingdom and the United States. The market's reaction suggests a re-evaluation of the company's financial outlook amidst these strategic and regulatory developments.

Strategic Reorientation Amidst Regulatory Landscape

AstraZeneca has recently scaled back or paused major investments within the United Kingdom, including a planned £200 million expansion of its research site in Cambridge and a £450 million revamp of its vaccine site in Liverpool. These decisions follow ongoing disputes with the UK government over drug pricing and reduced financial support, contributing to a broader trend of pharmaceutical firms re-evaluating their UK commitments.

In stark contrast, the company is intensifying its focus on the United States market, which accounts for nearly half of its total sales. Under increasing pressure from the US government regarding pharmaceutical investment, AstraZeneca has unveiled plans for a substantial $50 billion investment in the US by 2030. This strategic pivot is seen as a measure to mitigate the impact of potential tariffs and solidify its presence in a crucial market. The company also intends to elevate its New York listing to parity with its primary London listing, although it asserts its headquarters and primary listing will remain in the UK. The company's long-serving chief executive, Sir Pascal Soriot, has openly expressed frustrations over the UK's regulatory environment and its rejection of certain innovative drugs.

Market's Valuation Discrepancies

The recent share rally has intensified discussions surrounding AstraZeneca's true valuation. A Discounted Cash Flow (DCF) analysis projects the company's intrinsic value at $239.10 per share, indicating a potential 46.5% discount to the current market price, suggesting the stock may be significantly undervalued. However, other valuation metrics present a more complex picture. The company's current Price-to-Earnings (P/E) ratio of 32.1x closely aligns with Simply Wall St's proprietary 'Fair Ratio' of 33.3x, which incorporates growth and risk factors, suggesting a fair valuation by this specific metric. Conversely, when compared to industry peers, AstraZeneca's P/E ratio appears expensive against a peer average of 16.3x. Similarly, its forward P/E ratio, estimated between 18x-20x (or 15.20x by another account), surpasses that of Pfizer (~8.3x) and Novartis (~12.7x). Meanwhile, its Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization (EV/EBITDA) stands at 9.45, below its five-year average of 12.19, but still outperforming Pfizer's 7.47 while lagging Novartis's 11.16.

Pipeline Strength and Growth Trajectory

AstraZeneca's long-term growth prospects remain underpinned by a robust research and development (R&D) pipeline and a clear strategic vision. The company's R&D strategy emphasizes transformative therapies, including antibody-drug conjugates (ADCs), radioconjugates, and gene therapy. It targets the launch of 20 new medicines by 2030, supported by 196 R&D programs, with 19 new molecular entities (NMEs) in late-stage development. Notably, seven of these NMEs are anticipated to have Phase III readouts in 2025.

Oncology continues to be a cornerstone of the company's revenue, contributing 43% of the total, with flagship drugs like Tagrisso, Imfinzi, and Enhertu protected by patents extending into the 2030s. AstraZeneca is also diversifying into high-growth areas such as obesity treatments and gene therapy. Management has reiterated a goal of achieving an operating profit margin of approximately 35% and an ambitious revenue target of $80 billion by 2030, a target that Goldman Sachs views with increasing clarity.

Outlook and Regulatory Headwinds

Despite the positive momentum, AstraZeneca continues to navigate a complex regulatory landscape. Discussions around new US tariffs and the ongoing political conversations regarding Medicare drug pricing introduce an element of uncertainty. While Goldman Sachs analysts suggest a limited impact from potential drug tariffs, assuming they are calculated based on transfer prices and given the company's efforts in segregating its supply chain, the implications of the Inflation Reduction Act (IRA) and the redesign of the Medicare Part D plan are expected to affect total revenue by "a few percentage points" in 2025. The company has also emphasized its commitment to innovation, with its management advocating for increased healthcare budgets in European countries to support higher drug prices. Future developments in these policy arenas will be critical for shaping AstraZeneca's trajectory in the coming quarters.